Sacituzumab govitecan 180mg powder for solution for infusion vials
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Sacituzumab govitecan
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Sacituzumab govitecan
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Sacituzumab govitecan
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Sacituzumab govitecan on the MHRA register
Trodelvy 180mg powder for concentrate for solution for infusion vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(4)
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (TA819)
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (TA862)
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 23 · Randomised trials: 10 · 2015–2026
Showing the 50 most relevant studies, sorted by most relevant.
H. Rugo, A. Bardia, F. Marmé, et al.
Lancet, 2023
T. Powles, S. Tagawa, C. Vulsteke, et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 2025
- Carcinoma, Transitional Cell
- Urologic Neoplasms
- Camptothecin
R. Sultana, Sylvia Chen, E. Lim, et al.
BJC Reports, 2024
Yaping Zhang, Jian Chen, Xiaoyan Wang, et al.
Frontiers in Oncology, 2025
O. Gluz, Bing-He Xu, R. Nanda, et al.
Therapeutic Advances in Medical Oncology, 2025
Jue Wang, Shengyou Lin, Jialin Zhang, et al.
European Journal of Clinical Pharmacology, 2025
- Breast Neoplasms
- Camptothecin
- Cell Adhesion Molecules
Piekarz J, Picheta N, Pobideł J, et al.
2025
- Camptothecin
- Immunoconjugates
- Antibodies, Monoclonal, Humanized
Xu YX, Shen Q, Lu XF, et al.
2025
ObjectiveSacituzumab govitecan (SG) has emerged as a therapeutic option for various cancers. Increasing reports of SG-associated neutropenia have attracted attention, emphasizing the need to fully characterize this risk.MethodsThis study conducted a retrospective pharmacovigilance analysis using the Food and Drug Adverse Event Reporting System (FAERS) database. Cases of neutropenia associated with SG were extracted from the second quarter of 2020 through the second quarter of 2025 for disproportionality analysis. Additionally, a meta-analysis was performed on randomized controlled trials (RCTs) comparing SG (experimental group) with chemotherapy drugs (control group), retrieved from CNKI, Wanfang, VIP, PubMed, the Cochrane Library, EMBASE, and Web of Science.ResultsIn the FAERS, 500 cases of neutropenia were associated with SG treatment. Among antibody-drug conjugate (ADC) drugs, SG exhibited the strongest positive signal (reported odds ratio (ROR) = 17.91, 95% CI: 16.39-19.56). Subgroup analysis revealed that this signal widely existed in different gender, age, reporting groups and initial indications. Most events occurred within 30 days of initial initiation. Gender (10 days for males vs. 13 days for females, P P P P P P > 0.05), the control group exhibited a tendency toward higher risk, and the SG group demonstrated a significantly lower incidence of grade ≥3 AEs compared to controls (P *1/*28 and UGT1A1*28/*28 genotypes compared to those with the UGT1A1*1/*1 genotype (P > 0.05).ConclusionThe combined analysis supports an elevated risk of neutropenia associated with SG. This AE exhibits significant cancer species specificity. Early intervention and management of neutropenia are therefore of considerable clinical importance.
Abstract licence: CC BY
Liang S, Liao W, Jiang J, et al.
2026
- Camptothecin
- Antineoplastic Agents
- Immunoconjugates
Güren AK, Kırcalı MF, Sarı M, et al.
2026
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
16 hours
Mechanism
Sacituzumab govitecan is an antibody-drug conjugate (ADC) targeting TROP-2-expre…
Food interactions
None known
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
10 mg/k
Half-life
16 hours
[L13002][A193731]
Protein binding
10 mg/k
Volume of distribution
0.045 L/kg
[L13002]
Metabolism
Elimination
Clearance
0.002 L/h
[L13002]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed under the brand name Trodelvy™ by Immunomedics, Inc.; it is currently indicated under accelerated approval for the treatment of mTNBC patients who have undergone two or more prior therapies. As a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects.[A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372][L47601]
[L45103][L47596][L47606]
It is also indicated for the treatment of unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
[L45103][L47596][L47606]
These indications are approved in the US, Canada, and Europe.
In the US, sacituzumab govitecan is additionally indicated for the treatment of locally advanced or metastatic urothelial cancer in adult patients who have received previous platinum-based therapy and either a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. This indication has been approved under accelerated approval, and continued approval may be contingent on the demonstration of clinical benefit in confirmatory trials.
[L13002]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 467 interactions
[L13002]
The proposed mechanism of action first involves the binding of the RS7 component to TROP-2, which is highly expressed on the cell surface of multiple cancers.[A193671] Binding of RS7 to TROP-2 results in rapid internalization of bound antibody[A193656][A193659], and the likely intracellular release of SN-38 via hydrolysis of the CL2A linker[L13002][A193674]. SN-38 is an active metabolite of the anti-cancer drug [irinotecan], which is thought to work primarily through inhibition of DNA topoisomerase I, leading to DNA damage and eventual cell death.[A193665] In addition, recent work has identified a possible secondary mechanism of action for SN-38 by disrupting the binding of Far Upstream Binding Protein 1 (FUBP1) to the FUSE elements regulating oncogene expression.[A193668]
In addition to SN-38-mediated cell death, there is also some evidence that the RS7 component of the conjugate drug possesses antibody-directed cellular toxicity.[A193674][A193662]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L13002]
[L13002][A193731]
[A193731]
[L13002]
[L13002][A193665]
[L13002][A193665]
[L13002]
Proteins and enzymes this drug interacts with in the body
The free DNA strand then rotates around the intact phosphodiester bond on the opposing strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone (By similarity). Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells.
Involved in the circadian transcription of the core circadian clock component BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the BMAL1 promoter
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC L01FX17
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Sacituzumab govitecan
Additional database identifiers
Drugs Product Database (DPD)
23659
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11530
GeneCards
TACSTD2
Guide to Pharmacology
2837
UniProt Accession
TACD2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11986
GenAtlas
TOP1
GeneCards
TOP1
GenBank Gene Database
J03250
GenBank Protein Database
339806
UniProt Accession
TOP1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4004
GenAtlas
FUBP1
GeneCards
FUBP1
GenBank Gene Database
U05040
UniProt Accession
FUBP1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12530
GeneCards
UGT1A1
GenBank Gene Database
M57899
GenBank Protein Database
184473
Guide to Pharmacology
2990
UniProt Accession
UD11_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72